0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Potential confounders in linking elevated S100A8/A9 to left ventricular dysfunction in septic shock patients

      letter
      1 , , 2 , 2
      Critical Care
      BioMed Central

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Jakobsson et al. investigated the role of S100A8/A9, a pro-inflammatory alarmin, in sepsis-induced myocardial dysfunction (SIMD). They concluded that elevated S100A8/A9 is associated with the development of left ventricular (LV) dysfunction in severe sepsis patients [1]. Patients 18 years of age and older admitted to the intensive care unit (ICU) with septic shock (per Sepsis III) were included in this study [1]. Thirty-five out of sixty-two (56%) patients had LV dysfunction. Plasma S100A8/A9 was significantly higher in LV dysfunction patients (20.1 μg/mL vs. 7.4 μg/mL, P = 0.009). Nearly half of critically ill patients, especially with septic shock, develop acute kidney injury (AKI), and 20–25% require renal replacement therapy (RRT) within the first ICU week [2]. Considering S100A8 (10.8 kDa) and S100A9 (13.2 kDa) molecular weights, as well as the molecular weight of the S100A8/A9 heterodimer (24 kDa) [3], continuous RRT (CRRT)—which has a cut-off value of 35–40 kDa—might eliminate these molecules, impacting bio marker levels, and potentially leading to artificially decreased S100A8/A9 levels [4, 5]. The absence of CRRT/RRT in the criteria and its impact on each group is a potential major comfounding factor that could heavily influence results [4, 5]. In a clinical setting, this could lead to inaccurate prognosis and unadapted support. It is necessary that a sensitivity analysis should be done after the exclusion of CRRT/RRT patients to clarify the performance of these biomarkers when they are not artificially removed by an extracorporeal purification technique [5].

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from The Intensive Care Over Nations audit

          Background Acute kidney injury (AKI) is a common complication of critical illness and is associated with worse outcomes. However, the influence of deterioration or improvement in renal function on clinical outcomes is unclear. Using a large international database, we evaluated the prevalence and evolution of AKI over a 7-day period and its effects on clinical outcomes in septic and non-septic critically ill patients worldwide. Methods From the 10,069 adult intensive care unit (ICU) patients in the Intensive Care Over Nations database, all those with creatinine and urine output data were included in this substudy. Patients who developed sepsis during the ICU stay (≥ 2 days after admission) were excluded. AKI was evaluated within 72 hours after admission and before discharge/death up to day 7 according to the Acute Kidney Injury Network (AKIN) criteria. Results A total of 7970 patients were included, 59% of whom met AKIN criteria for AKI within the first 72 hours of the ICU stay. Twenty-four per cent of patients had sepsis on admission, of whom 68% had AKI, compared to 57% of those without sepsis on admission (p < 0.001). AKIN stage 3 (40% vs 24%, p < 0.001) and use of renal replacement therapy (20% vs 5%, p < 0.0001) were more prevalent in patients with sepsis. Patients with sepsis and AKIN stage 3 were less likely to improve to a lower stage during the 7-day follow-up period than non-septic patients with AKIN stage 3 (21% vs 32%, p < 0.0001). In-hospital mortality was related to severity of AKI and was reduced in patients in whom AKI improved compared to those who remained stable or deteriorated, but remained higher than in patients without AKI, even if there was apparent full recovery at day 7. Conclusion These findings illustrate the different kinetics of AKI in septic and non-septic ICU patients and emphasize the important impact of AKI on mortality rates even when there is apparent full renal recovery at day 7. Electronic supplementary material The online version of this article (10.1186/s13054-018-2112-z) contains supplementary material, which is available to authorized users.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            S100 family proteins in inflammation and beyond.

            The S100 family proteins possess a variety of intracellular and extracellular functions. They interact with multiple receptors and signal transducers to regulate pathways that govern inflammation, cell differentiation, proliferation, energy metabolism, apoptosis, calcium homeostasis, cell cytoskeleton and microbial resistance. S100 proteins are also emerging as novel diagnostic markers for identifying and monitoring various diseases. Strategies aimed at targeting S100-mediated signaling pathways hold a great potential in developing novel therapeutics for multiple diseases. In this chapter, we aim to summarize the current knowledge about the role of S100 family proteins in health and disease with a major focus on their role in inflammatory conditions.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Reliability of biomarkers of sepsis during extracorporeal therapies: the clinician needs to know what is eliminated and what is not

              Background The evolution of renal replacement therapy (RRT) techniques, and the increasing number of critically ill patients receiving extracorporeal therapies, has presented clinicians with a significant problem: if biomarkers are removed by RRT, can they still be considered reliable in their role of guiding diagnosis and treatment? The most commonly used RRT techniques in intensive care units (ICUs) can be classified into three categories: continuous renal replacement therapy (CRRT), intermittent hemodialysis (IHD), and hybrid techniques such as those performed with sorbent devices and plasma exchange (PE). These techniques remove substances from the plasma via convection, adsorption, or a combination of the two. Various factors determine the degree of removal, including molecular weight (MW) and charge, and the type of membrane and RRT technique used. IHD has a cut-off of 5 kDa in most cases and the risk of eliminating biomarkers is small. For CRRT, the cut-off value of the membranes is about 35 kDa, and as a result, filtration of a significant number of biomarkers may occur. New highly adsorptive membranes (HAMs), such as the acrylonitrile 69-surface treated (AN69-ST), are being used more frequently in ICUs [1]. This means that biomarkers with a MW above 35 kDa, while not removed by convection, may potentially be removed in a significant quantity by adsorption. With hybrid devices like CytoSorb, removal of hydrophobic substances with a MW up to 55 kDa occurs via selective binding [2]. PE has a cut-off of 1000 kDa and removes not only biomarkers but also a range of other substances including clotting factors and immunoglobulins. Clearance of a substance cannot always be predicted from MW and RRT membrane characteristics alone, highlighting the need for further studies to determine biomarker levels pre- and post-device for different CRRT techniques. For example, the relatively small MW (25 kDa) of high mobility group protein B1 (HMGB1), a damage-associated molecular pattern (DAMP) and marker of outcome, in theory does not prohibit its removal by convection. However, HMGB-1 is not eliminated by convection and is only effectively cleared through adsorption by HAMs like AN69-ST [3]. This occurs because it has a flat shape, and this prevents its passage through a CRRT membrane, despite its small MW. The degree of biomarkers removal by RRT, with the consequent effect on their serum levels, is essential information for clinicians (Fig. 1). Fig. 1 Biomarker molecular weight and removal by CRRT membranes Biomarkers eliminated by CRRT and sorbents C-reactive protein (CRP) is the most commonly used biomarker of inflammation. While often thought of as a pentamer with a MW of 125 kDa, CRP is predominantly present as a monomer (mCRP, MW 22–25 kDa) in the blood of septic patients and as such is removed by all forms of CRRT. Substantial amounts can also be eliminated via adsorption, by both conventional CRRT membranes and the CytoSorb device [4]. Procalcitonin (PCT), a biomarker used to detect (and exclude) the presence of infection and to monitor response to treatment, has a MW of 13.5 kDa and has been detected in the ultrafiltrate of patients undergoing CRRT [5]. Most of the PCT is eliminated by convection, but adsorption also contributes to elimination during the first hours of treatment [5]. B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), biomarkers of cardiac dysfunction and outcome in sepsis, are also highly likely to be easily cleared by CRRT given their low MWs (3.5 kDa for BNP and 8.5 kDa for NT-proBNP) [6]. Mid-regional pro-adrenomedullin (MR-pro-ADM), a biomarker of sepsis severity and response to treatment, has a MW between 4 and 5.5 kDa, and its plasma concentration has been shown to decrease by 45–65% if a high-flux membrane is used [7]. Recently, presepsin has also been identified as a diagnostic biomarker of sepsis [8]. It has a MW of 13 kDa, which theoretically means that it could be subject to significant convective elimination. Given that RRT artificially decreases creatinine levels, a patient under RRT should be considered as having the full acute kidney injury in any score. Biomarkers not eliminated by CRRT or sorbents but needing further investigation Endocan is a diagnostic and prognostic biomarker for sepsis and acute respiratory distress syndrome [9]. CRRT with a membrane cut-off of 35 kDa is unlikely to remove endocan (MW 40 kDa), but removal may possibly occur by adsorption when HAMs are used [10]. Pentraxin 3 (PTX3), a marker of sepsis severity and a diagnostic marker for ventilator-associated pneumonia [11], has a MW of 35 kDa and thus, in theory, can be removed by CRRT. However, a recent study demonstrated little or no clearance or absorption by the filter during CVVH [12]. Heparin binding protein (HBP), a predictor of sepsis-induced organ dysfunction [13], has a MW of 37 kDa and as such should not be removed by convection. HBP has been detected in the effluent of patients undergoing CRRT, without a consistent decrease in plasma levels [14]. Studies are needed to investigate whether adsorption is possible. Osteopontin (OPN) is a predictor of outcome in critically ill patients [15]. A highly negatively charged protein with a MW of 32 kDa, osteopontin can theoretically be removed by CRRT, but at this time evidence is lacking. Table 1 summarizes all biomarkers described in this review with their MW, ability to be removed by convection and/or adsorption, and whether a study focusing on removal via RRT has been performed. Table 1 Biomarker molecular weight, potential removal by CRRT or sorbents, and summary of the available studies and the studies that need to be realized of levels in the context of RRT Biomarker Molecular weight (kDa) Elimination by CRRT Elimination by sorbents Existing studies Studies needed mCRP 20–25 + + + + PCT 14.5 + + + + BNP 3.5 + + + + NT-ProBNP 8.5 + + + + HMGB-1 25 + (adsorption only) + + – OPN – + – + Endocan 40 – + – + MR-pro-ADM 4–5.5 + – – + PTX3 35 – + + + Presepsin 13 + + + + HBP 37 – + – + kDa kilodalton, CRRT continuous renal replacement therapy, mCRP monomeric C-reactive protein, PCT procalcitonin, NT-ProBNP N-terminal pro-hormone of brain natriuretic peptide, OPN osteopontin, HMGB-1 high mobility group protein B1, MR-pro-ADM mid-regional pro-adrenomedullin, HBP heparin binding protein Conclusions It is likely that many sepsis biomarkers may be removed by convection, and therefore, their reliability as markers in patients undergoing CRRT is under question. Furthermore, the increasing use of HAMs makes the removal of many biomarkers even more likely. It is possible that some biomarkers may still have utility in the role of guiding diagnosis and treatment of critically ill patients on CRRT; however, further studies exploring biomarker elimination by CRRT are needed to confirm this. The development of new reference ranges for biomarkers in the setting of RRT would also be an interesting avenue of study. Beyond their utility as biomarkers, there are still many other questions to answer, such as whether removal of these, and other, substances by CRRT may result in benefit or harm.
                Bookmark

                Author and article information

                Contributors
                patrick.honore@chuuclnamur.uclouvain.be
                Journal
                Crit Care
                Critical Care
                BioMed Central (London )
                1364-8535
                1466-609X
                6 December 2023
                6 December 2023
                2023
                : 27
                : 480
                Affiliations
                [1 ]GRID grid.7942.8, ISNI 0000 0001 2294 713X, CHU UCL Godinne Namur, UCL Louvain Medical School, ; Campus Godinne, Avenue G Thérasse 1, 5530 Yvoir, Belgium
                [2 ]GRID grid.4989.c, ISNI 0000 0001 2348 0746, ULB University, ; Brussels, Belgium
                Article
                4769
                10.1186/s13054-023-04769-z
                10699055
                38057840
                bbb954a8-a702-4441-8ce8-9d6ca9b3d829
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 27 November 2023
                : 29 November 2023
                Categories
                Matters Arising
                Custom metadata
                © BioMed Central Ltd., part of Springer Nature 2023

                Emergency medicine & Trauma
                Emergency medicine & Trauma

                Comments

                Comment on this article